Bringing teams together to support the communities we serve. Our Patient Services team joined NAMIWalks St. Louis with Otsuka Patient Assistance Foundation, Inc. (OPAF) as part of Team Patient Minded, continuing a shared commitment to mental health advocacy. This year, the team raised $1,317, for a collective $4,830 over the past 3 years, to help expand access to education, support, and resources for individuals and families affected by mental illness. A special thank you to Melissa Diaz, Melanie Gibson, Faiza Dawid, and everyone who helped make this effort possible. #MentalHealthAwareness #CommunityImpact #PatientSupport #NAMI
Info
EVERSANA® is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com.
- Website
-
http://eversana.com
Externer Link zu EVERSANA
- Branche
- Arzneimittelherstellung
- Größe
- 5.001–10.000 Beschäftigte
- Hauptsitz
- Chicago, IL
- Art
- Privatunternehmen
- Spezialgebiete
- Regulatory, Management & Specialty Consulting, Research & Insights, Global Pricing Strategies, Patient, Payer & Provider Marketing Services, Field Medical, Market Access & Sales , Global Channel Management & 3PL, Specialty Pharmacy & In-Home Nursing, HUB & Adherence Solutions, Affordability Programs, Medical Communications & Pharmacovigilance, Revenue Management, Digital Strategies & Therapy Transformation, Patient Analytics Services, Integrated Patient-Level Data, Commercial Analytics Platform, RWE & HEOR Global Services, Global Launch Expertise und Payer Reimbursement Strategies
Orte
Beschäftigte von EVERSANA
Updates
-
Anyone can pilot AI. Very few can operate it. AI requires governed workflows with human oversight that perform consistently in practice. That level of execution is what separates teams that keep up from those that pull ahead. See how this operates in practice: https://ow.ly/3IuH50Z1RL4 #AIinPharma #Commercializion #LifeSciences
-
As the biopharma industry continues to evolve, Medical Affairs teams are facing increasing pressure to adapt and deliver. EVERSANA’s Medical Affairs Excellence and Enablement supports global teams in strengthening execution, scaling capacity on demand, and enhancing performance across the product lifecycle. This white paper presents a modern, flexible framework to address industry challenges while safeguarding quality, compliance, and strategic impact. Read more: https://ow.ly/Yzoj50YRzYE #MedicalAffairs #OperationalExcellence #PharmaStrategy #LaunchExcellence #LifeSciences #Biopharma
-
Amber Svardal MSN, RN, OCN doesn’t just talk about innovation, she puts it into practice every day! From sorting through massive medical congress agendas to helping teams uncover key insights, Amber leverages AI in new and creative ways when tackling complex tasks – creating more time for meaningful conversations and smarter decision-making. Thank you, Amber, for always leading with curiosity and a constant desire to improve how we work! This is Purpose in Action: real people, real work, and real impact – happening every day across EVERSANA. Discover the EVERSANA difference: https://ow.ly/OLa550YZ6mQ #AI #LifeSciencesInnovation #AlwaysInnovate #EVERSANA #PurposeInAction
-
The future of pharma pricing and market access unfolds at PPIC 2026, June 9–11, in Basel, Switzerland. Join global leaders, policymakers, and industry experts for practical insights and open discussion on the policy, reimbursement, and access dynamics shaping pharmaceutical strategy across markets. Explore the preliminary agenda and register now: https://lnkd.in/ehgcY_i2
-
-
Members of our team are excited to attend #BIO2026. BIO International is where innovation meets opportunity. We’re looking forward to connecting with biopharma leaders to discuss how our integrated commercial partnerships help turn promising science into predictable, scalable success. Interested in reducing risk and strengthening enterprise value while maintaining control and flexibility? Schedule time to connect and learn how: https://ow.ly/6Z6I50YMUbz
-
“Access” is no longer just a benefit — it’s a strategic lever. As employers face rising demand for GLP‑1 therapies, new direct‑to‑employer models are emerging to reduce complexity and improve outcomes. Deanna Horner shares what’s changing and what it means for the future of care. Read more https://lnkd.in/dXnw5dTA Waltz Health #HealthcareAccess #GLP1 #Commercialization #LifeSciences
-
The instinct to build AI in-house is understandable. The harder question is whether that path accelerates impact or quietly slows it down. See the full perspective: https://lnkd.in/dKr4Fe3j #LifeSciences #AIInPharma
-
-
Is your EU launch strategy at risk? A single PICO misalignment for the new Joint Clinical Assessment can lead to costly delays and rework. The question is no longer if you should predict the PICO, but how. Is AI, a literature review, or a survey the right tool? In ISPOR’s Value & Outcomes Spotlight feature, EVERSANA experts Pamela V. and Shivani Shah, alongside industry experts, explore why a blended, tailored strategy is the only practical path forward. Navigate the JCA with confidence. Read the full article: https://ow.ly/cJPV50YVJnM
-
If a biotech is looking to out-license, is Phase 3 really the right time? Our experts analyzed five years of late-stage and post-approval licensing deals and uncovered powerful insights about valuation, deal frequency, upfront cost, and probability of growth. Get the full analysis here: https://ow.ly/6NsK50YIc4Y
-